JP2004256413A - Animal cell culture raw material - Google Patents

Animal cell culture raw material Download PDF

Info

Publication number
JP2004256413A
JP2004256413A JP2003047144A JP2003047144A JP2004256413A JP 2004256413 A JP2004256413 A JP 2004256413A JP 2003047144 A JP2003047144 A JP 2003047144A JP 2003047144 A JP2003047144 A JP 2003047144A JP 2004256413 A JP2004256413 A JP 2004256413A
Authority
JP
Japan
Prior art keywords
cells
animal cell
cell culture
animal
raw material
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003047144A
Other languages
Japanese (ja)
Other versions
JP4381000B2 (en
Inventor
Mutsumi Takagi
睦 高木
Toshiomi Yoshida
敏臣 吉田
Kazusuke Kubo
一介 久保
Kazuyoshi Toma
一孔 戸澗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Kasei Corp
Noguchi Institute
Original Assignee
Asahi Kasei Corp
Noguchi Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Kasei Corp, Noguchi Institute filed Critical Asahi Kasei Corp
Priority to JP2003047144A priority Critical patent/JP4381000B2/en
Publication of JP2004256413A publication Critical patent/JP2004256413A/en
Application granted granted Critical
Publication of JP4381000B2 publication Critical patent/JP4381000B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To provide an animal cell culture raw material with a simply synthesizable monosaccharide derivative in a simplified process without using a mixture of complex polysaccharides originating from natural products, such as heparin. <P>SOLUTION: This galactose-6-sulfate derivative represented by formula (1) [R is H or O(CH<SB>2</SB>)<SB>n</SB>CH<SB>3</SB>; (m) is an integer of 2 to 6; (n) is an integer of 11 to 17]. The animal cell culture raw material prepared by immobilizing the galactose-6-sulfate structure on the surface of a material. The method for culturing an animal cell is characterized by preliminarily coating the surface of a culture raw material with the compound represented by formula (1) and then culturing the animal cell. <P>COPYRIGHT: (C)2004,JPO&NCIPI

Description

【0001】
以下で、DMFはジメチルホルムアミドの略号である。
【0002】
【発明の属する技術分野】
本発明は、硫酸糖誘導体を利用した動物細胞培養素材、および、動物細胞培養法に関するものである。
【0003】
【従来の技術】
我々はこれまでに、簡単な構造を持つ低分子である、各種の糖脂質アナログを合成し(特許文献1、2参照)、その脂質類似構造の疎水性を利用して、細胞培養素材に固定化することにより、単糖誘導体でも肝臓細胞の培養等に有効に利用できることを示してきた(特許文献3、非特許文献1、2参照)。しかし、硫酸基を持つ化合物の合成は行っていなかった。
【0004】
硫酸基を持つ糖鎖には、ヘパラン硫酸、デルマタン硫酸等の様々な生理作用を有するものが知られている。例えば、造血が行われている器官である骨髄中には種々の細胞外マトリックス成分と共にヘパリンなどの硫酸糖が多量に含まれている。これら硫酸糖は、生体内で極微量で種々の生理活性を示す多くのサイトカインや増殖因子と親和性が高く、これらの因子の局在化を生じ、造血作用などの種々の生理作用を促進していると言われている。
【0005】
こうした硫酸糖の機能を利用して、動物細胞培養を効率的に行おうとする試みが種々行われている。例えば、ヒト造血細胞の培養液にサイトカインを添加する際にヘパリンを共存させるとサイトカインの造血細胞増殖促進作用が大幅に増強されることが知られており、これはサイトカインとヘパリンとの間に親和性があるためとされている(非特許文献3参照)。そこで、遊離のヘパリンを用いるのではなく、動物細胞が接着する基質表面にヘパリンを固定化することにより、動物細胞近傍にサイトカインを局在化させ、より効果的に細胞培養を促進しようとする試みもなされてきた。具体的には、細胞培養用ディッシュ表面にヘパリンを固定するために、まず、正電荷を有するキトサンを固定化し、固定化されたキトサンにヘパリンやコンドロイチン硫酸をイオン結合により固定化する。引き続き、このディッシュにサイトカインとして幹細胞因子(SCF、5 ng/ml)、インターロイキン3(10 ng/ml)を加えた上で、ヒト臍帯血CD34表面抗原陽性細胞を培養すると、ヘパリン等を用いず、サイトカインだけを用いて培養する場合に比べ、CD34表面抗原陽性細胞を20〜30倍多く増殖できた(非特許文献4参照)。また、細胞の接着基質であるポリエステル表面に酸素プラズマ放電で水酸基を導入し、これに続く数段の反応でヘパリンを共有結合により固定化する方法も開発された(非特許文献5参照)。
【0006】
しかし、ヘパリンやコンドロイチン硫酸等は天然由来で、複雑な構造を持つ多糖の混合物であり、工業的にはこれをより簡単な化合物で置き換えることが望ましい。また、これまでの方法によって細胞培養素材に硫酸糖を固定化するためには、複数の工程を必要としていた。
【0007】
【特許文献1】
特開2001−122889号公報
【特許文献2】
特開2002−30091号公報
【特許文献3】
特開2002−27977号公報
【非特許文献1】
ジャーナル・オブ・アーティフィシャル・オーガンズ(J. Artif. Organs)、2001年、4巻、p.315−319
【非特許文献2】
ジャーナル・オブ・バイオサイエンス・アンド・バイオエンジニアリング(J. Biosience Bioengineering)、2002年、93巻、p.437−439
【非特許文献3】
ブラッド(Blood)、2000年、95巻、p.147−155
【非特許文献4】
ステムセルズ(Stem Cells)、1999年、17巻、p.295−305
【非特許文献5】
バイオマテリアルズ(Biomaterials)、2000年、21巻、p.121−130
【0008】
【発明が解決しようとする課題】
本発明の目的は、ヘパリンの様な天然由来の複雑な多糖の混合物を用いずに、簡単に合成できる単糖誘導体を用いて、従来よりも簡便な工程で動物細胞培養素材を提供することにある。
【0009】
【課題を解決するための手段】
上記課題を鋭意検討した結果、本発明者らは、ガラクトース硫酸誘導体をヘパリン等の代りに用いれば、上記課題を解決できることを見出し、本発明を完成した。
具体的には、式(1)で示される新規なガラクトース−6−硫酸誘導体をコーティングしたポリエステル不織布を用いて種々のサイトカインを含んだ造血細胞培養上清を用いた造血細胞の培養を行うと、何もコーティングしていない不織布を用いた場合に比較して、通常の種々のサイトカインを含んだ造血細胞培養上清を用いた造血細胞の培養に適用して、造血細胞の増殖活性を向上させることを見出し、本発明を完成するに至った。
【化2】

Figure 2004256413
(ただし、式中で、RはHまたはO(CHCHを、mは2から6の整数を、nは11から17の整数を表す。)
【0010】
即ち、本発明は、式(1)で示される化合物、および、ガラクトース−6−硫酸構造を素材表面に固定化した動物細胞培養素材、および、式(1)で示される化合物を、予め培養素材表面にコーティングした後に細胞培養を行うことを特徴とする動物細胞培養法を提供する。
【0011】
以下に本発明を詳細に説明する。
式(1)の化合物の合成は、我々がこれまでに報告した方法(特開2001−122889号公報、特開2002−27977号公報)に従って合成した硫酸基を持たないガラクトース誘導体に、三酸化硫黄・トリメチルアミン錯体や三酸化硫黄・ピリジン錯体等の適当な硫酸化剤を反応させることによって調製することができる。6位水酸基の反応性が一番高いため、ガラクトース部分の水酸基の保護を必要とせず、1工程でガラクトース−6−硫酸誘導体が得られる。
上記の製造方法で得られたガラクトース−6−硫酸誘導体はエタノールに可溶であり、そのエタノール溶液を任意の形状を持った疎水表面を有する培養素材に塗布し、アルコールを除去することで容易に固定化することができる。この様にガラクトース−6−硫酸誘導体を、ポリエステル、ポリスチレン等の様々な疎水性表面を有する培養素材に固定化して、動物細胞培養用の培養素材とする。
【0012】
動物細胞の培養は、以下の様に行う。
まず、培養素材に式(1)で示される化合物を上記の方法で固定化する。引き続き、通常の培地を用いて目的とする動物細胞の培養を通常使用される条件で行うことができる。必要に応じて、サイトカイン等の微量成分を予め培地に添加する、あるいは、培地中に細胞自身により生産されるサイトカイン等の微量成分を用いる、あるいは、サイトカイン等の微量成分を含む別途調製した培養上清を用いる等の手段を用いて、ガラクトース−6−硫酸誘導体を固定化した培養素材にサイトカイン等の微量成分を予め接触させた後、目的とする動物細胞の培養を通常使用される条件で行うこともできる。
【0013】
本発明で用いる動物細胞は、昆虫および動物由来の細胞であり、動物の種類としては鳥類、爬虫類、両生類、魚類、哺乳類などを挙げることができる。哺乳類動物としては、たとえばヒト、サル、ウシ、ブタ、ヒツジ、ウマ、ネズミなどを例としてあげることができる。また、動物から採取してから一般的に50回程度までの限られた回数のみ分裂、増殖できる初代細胞および動物から採取された後一般に50回以上の多数回分裂、増殖できる細胞株の両方とも用いることができる。初代細胞の例として、ラット初代肝細胞、マウス初代骨髄細胞、ブタ初代肝細胞、ヒト初代造血細胞などを挙げることができる。造血細胞の例として、マウス骨髄造血細胞、マウス末梢血細胞、ヒト骨髄細胞、ヒト骨髄単核細胞、ヒト末梢血有核細胞、ヒト臍帯血細胞、ヒト臍帯血単核造血細胞などを挙げることができる。細胞株の例としては、チャイニーズハムスター卵巣細胞株(CHO細胞)、ヒト子宮癌細胞株HeLa細胞、アフリカミドリザル腎細胞株Vero細胞、ヒト肝ガン細胞株Huh 7細胞などを挙げることができる。また、以上にあげた細胞に対して、プラスミドの導入、ウイルス感染などの手段により遺伝子操作を施して得られた細胞も本発明で用いることができる。CHO細胞とは、チャイニーズハムスターの卵巣組織から分離された全ての細胞株およびそれらに遺伝子操作を施して得られた細胞株であり、たとえばCHO−K1株(ATCC CCL61)、CHO 1−15500株(ATCC CRL−9606)、CHO DG44株などを例としてあげることができる。
【0014】
【発明の実施の形態】
以下に、本発明を更に具体的に説明するが、本発明はこれに限定されるものではない。
【0015】
【実施例1】
(N−(O−β−(6−O−スルホガラクトピラノシル)−6−オキシヘキシル)−3,5−ビス(ドデシロキシ)ベンズアミドの合成)
N−(O−β−ガラクトピラノシル−6−オキシヘキシル)−3,5−ビス(ドデシロキシ)ベンズアミド( 51.7 mg, 0.0687 mmol )をDMF 2ml に溶解し、三酸化硫黄・トリメチルアミン錯体( 336 mg, 2.41 mmol )を加え、アルゴン雰囲気下、2時間撹拌した。反応液をそのままゲルろ過(LH−20、クロロホルム−メタノール,1:1)し、目的物を含む画分を濃縮した。さらに、シリカゲルカラムクロマトフィー(クロロホルム−メタノール,2:1)により精製し、目的物( 14.2 mg, 0.0171 mmol )を得た。MALDI−TOF/MS(マトリックス、ジヒドロキシ安息香酸):m/z 831.53 (C4377NO12Sとして計算:831.52,[M−H]
【0016】
【実施例2】
(硫酸糖脂質アナログが臍帯血前駆細胞増殖に及ぼす影響)
N−(O−β−(6−O−スルホガラクトピラノシル)−6−オキシヘキシル)−3,5−ビス(ドデシロキシ)ベンズアミド3.5 mgを200 mlのエタノールに溶かし−20℃で保存した。使用時に、この保存溶液1.8 mlにエタノール8.2 mlを加えて希釈した後に、24穴プレートと同じ断面積で厚さ100μmに裁断したポリエステル不織布(旭化成製Y−15050)を1枚入れた24穴プレートに1 mlずつ加え揮発させた。また、濃度による影響を検討するため、この溶液をエタノールでさらに10倍希釈して同様にポリエステル不織布にコーティングした。
【0017】
動物細胞として、ヒト臍帯血からフィコール密度勾配遠心分離により得られた単核造血細胞を用いた。
予め、ヒト臍帯血単核造血細胞1×10 cellsとヒト骨髄初代ストローマ細胞5×10 cellsとを、無血清無サイトカイン培地X−VIVO10(BioWhittaker,Walkersville,USA)を用いて、24ウェルプレート中で37℃,5%CO雰囲気下で1週間共培養した後、その培養上清を得た。
【0018】
上記のN−(O−β−(6−O−スルホガラクトピラノシル)−6−オキシヘキシル)−3,5−ビス(ドデシロキシ)ベンズアミドをコーティングした不織布、同じく10倍希釈した溶液でコーティングした不織布、または、コーティングしていない不織布、いずれかの不織布を入れた24穴プレートに、上記の培養上清を用いて、ヒト臍帯血単核造血細胞1×10 cellsを播種し、37℃、5%CO雰囲気下で1週間培養した。
その後、培養後の不織布および培養液の両方から回収した造血細胞を集め、コロニーフォーミングユニットアッセイを行い、培養後の造血前駆細胞の濃度を計数した。
【0019】
表1に示すように、培養後の造血前駆細胞濃度は、無処理の不織布に比べ、N−(O−β−(6−O−スルホガラクトピラノシル)−6−オキシヘキシル)−3,5−ビス(ドデシロキシ)ベンズアミドを10倍希釈してコーティングしたものでもほぼ同等、N−(O−β−(6−O−スルホガラクトピラノシル)−6−オキシヘキシル)−3,5−ビス(ドデシロキシ)ベンズアミドを1倍濃度でコーティングしたもので約1.6倍であり、明らかな増殖活性を示した。
【表1】
Figure 2004256413
【0020】
【発明の効果】
本発明は、ヘパリンの様な天然由来の複雑な多糖の混合物を用いずに、簡単に合成できる単糖誘導体を用いて、従来よりも簡便な工程で動物細胞培養素材を提供する。[0001]
In the following, DMF is an abbreviation for dimethylformamide.
[0002]
TECHNICAL FIELD OF THE INVENTION
The present invention relates to an animal cell culture material using a sulfated sugar derivative and an animal cell culture method.
[0003]
[Prior art]
We have synthesized various glycolipid analogs, which are small molecules with a simple structure (see Patent Documents 1 and 2), and immobilized them on cell culture materials by utilizing the hydrophobicity of the lipid-like structure. Thus, it has been shown that monosaccharide derivatives can be effectively used for culturing liver cells and the like (see Patent Literature 3, Non-Patent Literatures 1 and 2). However, a compound having a sulfate group was not synthesized.
[0004]
As sugar chains having a sulfate group, those having various physiological actions such as heparan sulfate and dermatan sulfate are known. For example, bone marrow, which is an organ where hematopoiesis is performed, contains a large amount of sulfated sugar such as heparin together with various extracellular matrix components. These sulfated sugars have high affinity for many cytokines and growth factors that show various physiological activities in a very small amount in vivo, cause localization of these factors, and promote various physiological actions such as hematopoiesis. Is said to be.
[0005]
Various attempts have been made to efficiently carry out animal cell culture using such functions of sulfated sugar. For example, it is known that coexistence of heparin when adding a cytokine to a culture solution of human hematopoietic cells greatly enhances the hematopoietic cell growth-promoting effect of the cytokine. (See Non-Patent Document 3). Therefore, instead of using free heparin, an attempt to localize cytokines in the vicinity of animal cells by immobilizing heparin on the surface of the substrate to which the animal cells adhere, thereby promoting cell culture more effectively. Has also been done. Specifically, in order to immobilize heparin on the surface of the cell culture dish, first, chitosan having a positive charge is immobilized, and heparin and chondroitin sulfate are immobilized on the immobilized chitosan by ionic bonding. Subsequently, after adding stem cell factor (SCF, 5 ng / ml) and interleukin 3 (10 ng / ml) as cytokines to the dish and culturing human cord blood CD34 surface antigen-positive cells, heparin was not used. The CD34 surface antigen-positive cells could be proliferated 20 to 30 times more than when cultured using only cytokines (see Non-Patent Document 4). Also, a method has been developed in which hydroxyl groups are introduced by oxygen plasma discharge onto a polyester surface, which is a cell adhesion substrate, and heparin is immobilized by covalent bonds in several subsequent reactions (see Non-Patent Document 5).
[0006]
However, heparin, chondroitin sulfate and the like are naturally occurring polysaccharide mixtures having a complex structure, and it is desirable to replace them with simpler compounds on an industrial scale. In addition, in order to immobilize sulfated sugar on the cell culture material by the conventional methods, a plurality of steps were required.
[0007]
[Patent Document 1]
JP 2001-122889 A [Patent Document 2]
Japanese Patent Application Laid-Open No. 2002-30091 [Patent Document 3]
Japanese Patent Application Laid-Open No. 2002-27977 [Non-Patent Document 1]
Journal of Artificial Organs (J. Artif. Organs), 2001, vol. 4, p. 315-319
[Non-patent document 2]
Journal of Bioscience and Bioengineering (J. Bioscience Bioengineering), 2002, Vol. 93, p. 437-439
[Non-Patent Document 3]
Blood, 2000, 95, p. 147-155
[Non-patent document 4]
Stem Cells, 1999, Vol. 17, p. 295-305
[Non-Patent Document 5]
Biomaterials, 2000, vol. 21, p. 121-130
[0008]
[Problems to be solved by the invention]
An object of the present invention is to provide an animal cell culture material using a simple sugar derivative that can be easily synthesized without using a mixture of complex polysaccharides derived from nature such as heparin and in a simpler process than before. is there.
[0009]
[Means for Solving the Problems]
As a result of intensive studies on the above problems, the present inventors have found that the above problems can be solved by using a galactose sulfate derivative instead of heparin or the like, and have completed the present invention.
Specifically, when hematopoietic cells are cultured using a hematopoietic cell culture supernatant containing various cytokines using a polyester nonwoven fabric coated with the novel galactose-6-sulfate derivative represented by the formula (1), Improve the proliferation activity of hematopoietic cells by applying it to culture of hematopoietic cells using hematopoietic cell culture supernatant containing normal various cytokines compared to the case of using non-coated non-woven fabric And completed the present invention.
Embedded image
Figure 2004256413
(Where R represents H or O (CH 2 ) n CH 3 , m represents an integer of 2 to 6, and n represents an integer of 11 to 17)
[0010]
That is, the present invention provides a method for preparing a compound represented by the formula (1), an animal cell culture material having a galactose-6-sulfate structure immobilized on the surface of the material, and a compound represented by the formula (1), There is provided an animal cell culture method characterized by performing cell culture after coating on the surface.
[0011]
Hereinafter, the present invention will be described in detail.
The synthesis of the compound of the formula (1) is carried out by adding a sulfur trioxide to a galactose derivative having no sulfate group, which is synthesized according to the method reported so far (JP-A-2001-122889, JP-A-2002-27977). -It can be prepared by reacting a suitable sulfating agent such as a trimethylamine complex or a sulfur trioxide / pyridine complex. Since the hydroxyl group at the 6-position has the highest reactivity, the galactose-6-sulfuric acid derivative can be obtained in one step without requiring protection of the hydroxyl group in the galactose moiety.
The galactose-6-sulfuric acid derivative obtained by the above-described production method is soluble in ethanol, and the ethanol solution is easily applied to a culture material having a hydrophobic surface having an arbitrary shape by removing the alcohol. Can be immobilized. In this way, the galactose-6-sulfate derivative is immobilized on a culture material having various hydrophobic surfaces such as polyester and polystyrene to obtain a culture material for animal cell culture.
[0012]
Culture of animal cells is performed as follows.
First, the compound represented by the formula (1) is immobilized on a culture material by the above method. Subsequently, the desired animal cell can be cultured using a usual medium under the conditions usually used. If necessary, a minor component such as a cytokine is added to the medium in advance, or a minor component such as a cytokine produced by the cell itself is used in the medium, or a separately prepared culture containing the minor component such as a cytokine is used. After contacting trace components such as cytokines with the culture material on which the galactose-6-sulfate derivative has been immobilized in advance by using a means such as washing, culture of the desired animal cells is carried out under generally used conditions. You can also.
[0013]
The animal cells used in the present invention are cells derived from insects and animals, and examples of animals include birds, reptiles, amphibians, fish, mammals, and the like. Examples of mammals include humans, monkeys, cows, pigs, sheep, horses, rats, and the like. In addition, both primary cells that can divide and proliferate only for a limited number of times, generally up to about 50 times from an animal, and cell lines that can divide and proliferate more than 50 times generally after being collected from an animal, Can be used. Examples of primary cells include rat primary hepatocytes, mouse primary bone marrow cells, pig primary hepatocytes, human primary hematopoietic cells, and the like. Examples of hematopoietic cells include mouse bone marrow hematopoietic cells, mouse peripheral blood cells, human bone marrow cells, human bone marrow mononuclear cells, human peripheral blood nucleated cells, human cord blood cells, human cord blood mononuclear hematopoietic cells, and the like. Examples of cell lines include a Chinese hamster ovary cell line (CHO cell), a human uterine cancer cell line HeLa cell, an African green monkey kidney cell line Vero cell, and a human liver cancer cell line Huh 7 cell. In addition, cells obtained by subjecting the above-described cells to genetic manipulation by means such as plasmid introduction or viral infection can also be used in the present invention. The CHO cells are all cell lines isolated from the ovarian tissue of Chinese hamster and cell lines obtained by subjecting them to genetic manipulation. For example, CHO-K1 strain (ATCC CCL61), CHO 1-15500 strain ( ATCC CRL-9606), CHO DG44 strain and the like.
[0014]
BEST MODE FOR CARRYING OUT THE INVENTION
Hereinafter, the present invention will be described more specifically, but the present invention is not limited thereto.
[0015]
Embodiment 1
(Synthesis of N- (O-β- (6-O-sulfogalactopyranosyl) -6-oxyhexyl) -3,5-bis (dodecyloxy) benzamide)
N- (O-β-galactopyranosyl-6-oxyhexyl) -3,5-bis (dodecyloxy) benzamide (51.7 mg, 0.0687 mmol) was dissolved in 2 ml of DMF, and sulfur trioxide / trimethylamine was dissolved. The complex (336 mg, 2.41 mmol) was added, and the mixture was stirred for 2 hours under an argon atmosphere. The reaction solution was directly subjected to gel filtration (LH-20, chloroform-methanol, 1: 1), and the fraction containing the desired product was concentrated. The product was further purified by silica gel column chromatography (chloroform-methanol, 2: 1) to obtain the desired product (14.2 mg, 0.0171 mmol). MALDI-TOF / MS (matrix, dihydroxybenzoic acid): m / z 831.53 (calculated as C 43 H 77 NO 12 S: 831.52, [M−H] )
[0016]
Embodiment 2
(Effect of sulfated glycolipid analog on cord blood progenitor cell proliferation)
Dissolve 3.5 mg of N- (O-β- (6-O-sulfogalactopyranosyl) -6-oxyhexyl) -3,5-bis (dodecyloxy) benzamide in 200 ml of ethanol and store at -20 ° C. did. At the time of use, after adding and diluting 8.2 ml of ethanol into 1.8 ml of this stock solution, one piece of a polyester nonwoven fabric (Y-15050 manufactured by Asahi Kasei Corporation) cut to a thickness of 100 μm with the same cross-sectional area as a 24-well plate is put. The mixture was volatilized by adding 1 ml each to a prepared 24-well plate. In order to examine the influence of the concentration, this solution was further diluted 10-fold with ethanol and coated on a polyester nonwoven fabric in the same manner.
[0017]
Mononuclear hematopoietic cells obtained by Ficoll density gradient centrifugation from human cord blood were used as animal cells.
Human cord blood mononuclear hematopoietic cells (1 × 10 5 cells) and human bone marrow primary stromal cells (5 × 10 5 cells) were previously transferred to a 24-well plate using a serum-free cytokine-free medium X-VIVO10 (BioWhittaker, Walkersville, USA). After co-culturing at 37 ° C. in a 5% CO 2 atmosphere for 1 week, the culture supernatant was obtained.
[0018]
The above non-woven fabric coated with N- (O-β- (6-O-sulfogalactopyranosyl) -6-oxyhexyl) -3,5-bis (dodecyloxy) benzamide, also coated with a 10-fold diluted solution Non-woven fabric, or uncoated non-woven fabric, 1 × 10 5 cells of human umbilical cord blood mononuclear hematopoietic cells were seeded on a 24-well plate containing any of the non-woven fabrics, using the above culture supernatant, and heated at 37 ° C. The cells were cultured under a 5% CO 2 atmosphere for one week.
Thereafter, hematopoietic cells collected from both the non-woven fabric after the culture and the culture solution were collected, a colony forming unit assay was performed, and the concentration of the hematopoietic progenitor cells after the culture was counted.
[0019]
As shown in Table 1, the concentration of hematopoietic progenitor cells after culturing was higher than that of the untreated nonwoven fabric, as compared with N- (O-β- (6-O-sulfogalactopyranosyl) -6-oxyhexyl) -3, N- (O-β- (6-O-sulfogalactopyranosyl) -6-oxyhexyl) -3,5-bis is almost the same even when 5-bis (dodecyloxy) benzamide is diluted 10-fold and coated. (Dodecyloxy) benzamide coated at 1-fold concentration was about 1.6-fold, showing clear growth activity.
[Table 1]
Figure 2004256413
[0020]
【The invention's effect】
The present invention provides an animal cell culture material using a simple sugar derivative that can be easily synthesized without using a mixture of complex polysaccharides derived from nature such as heparin, in a simpler process than before.

Claims (6)

式(1)で示されるガラクトース−6−硫酸誘導体。
Figure 2004256413
(ただし、式中で、RはHまたはO(CHCHを、mは2から6の整数を、nは11から17の整数を表す。)
A galactose-6-sulfuric acid derivative represented by the formula (1).
Figure 2004256413
(Where R represents H or O (CH 2 ) n CH 3 , m represents an integer of 2 to 6, and n represents an integer of 11 to 17)
ガラクトース−6−硫酸構造を素材表面に固定化した動物細胞培養素材。An animal cell culture material having a galactose-6-sulfate structure immobilized on the surface of the material. 請求項1に記載された式(1)で示される化合物を素材表面に固定化した動物細胞培養素材。An animal cell culture material in which the compound represented by the formula (1) according to claim 1 is immobilized on the material surface. 請求項1に記載された式(1)で示される化合物を、予め培養素材表面にコーティングした後に、細胞培養を行うことを特徴とする動物細胞培養法。An animal cell culturing method, comprising: coating a compound represented by the formula (1) according to claim 1 on the surface of a culture material in advance; and culturing the cell. 該動物細胞がヒト造血細胞であることを特徴とする請求項2または請求項3の動物細胞培養素材。4. The animal cell culture material according to claim 2, wherein the animal cells are human hematopoietic cells. 該動物細胞がヒト造血細胞であることを特徴とする請求項4の動物細胞培養法。The method for culturing animal cells according to claim 4, wherein said animal cells are human hematopoietic cells.
JP2003047144A 2003-02-25 2003-02-25 Animal cell culture material Expired - Fee Related JP4381000B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003047144A JP4381000B2 (en) 2003-02-25 2003-02-25 Animal cell culture material

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003047144A JP4381000B2 (en) 2003-02-25 2003-02-25 Animal cell culture material

Publications (2)

Publication Number Publication Date
JP2004256413A true JP2004256413A (en) 2004-09-16
JP4381000B2 JP4381000B2 (en) 2009-12-09

Family

ID=33113467

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003047144A Expired - Fee Related JP4381000B2 (en) 2003-02-25 2003-02-25 Animal cell culture material

Country Status (1)

Country Link
JP (1) JP4381000B2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005232064A (en) * 2004-02-18 2005-09-02 Noguchi Inst Sulfated saccharide library

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005232064A (en) * 2004-02-18 2005-09-02 Noguchi Inst Sulfated saccharide library
JP4675048B2 (en) * 2004-02-18 2011-04-20 公益財団法人野口研究所 Sulfate sugar library

Also Published As

Publication number Publication date
JP4381000B2 (en) 2009-12-09

Similar Documents

Publication Publication Date Title
US7470424B2 (en) Cultured cell construct containing spheroids of cultured animal cells and utilization thereof
EP1926742B1 (en) Cell surface coating with hyaluronic acid oligomer derivative
CN104955939B (en) The cultural method of the undifferentiated maintenance proliferation of stabilization for carrying out multipotent stem cells
KR20160117496A (en) Culture medium composition
JP2012533571A5 (en) Methods and compositions for in vitro and in vivo cartilage formation
CN1387565A (en) Hematopoietic differentiation of human embryonic stem cells
KR20010075288A (en) Three-dimensional cell incubation media and method for incubating cells by using the same
TW201930587A (en) Scaffold material for stem cell culture and method for stem cell culture using the same
CA3071363A1 (en) Additive composition for culture medium, additive compound for culture medium, and method for culture of cells or tissue using same
CN107916260B (en) Hydrogel-based single cell wrapping method, product and application
JP3014343B2 (en) Hepatocyte culture method
CN107936267B (en) Preparation method of zwitterionic starch-based stem cell amplification hydrogel and stem cell amplification and collection method
US20090305415A1 (en) Method for preserving proliferation and differentiation potential of undifferentiated cells
Evans Preparation of pure cultures of tumor macrophages
JP4381000B2 (en) Animal cell culture material
EP1885844A1 (en) Preparation and use of basement membrane particles
JP4381002B2 (en) Galactose disulfate derivative
JP4259876B2 (en) Oligosaccharide chain production method
JP5462617B2 (en) Cell culture substrate and method of using the same
JP4675048B2 (en) Sulfate sugar library
JP6478222B2 (en) Apoptosis inducer for undifferentiated cells
TWI820875B (en) Optimizing cell grafts, methods of their preparation, and their uses
KR102439335B1 (en) Bio-patch type cell therapy product for Regenerating skin comprising Placenta-derived stem cells
EP4299083A1 (en) Phenol derivative-modified, tissue-derived extracellular matrix derivative for construction of artificial tissue
JP2007117054A (en) Reverse transfection using polyion complex of nucleic acid with cationized polysaccharide

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20050615

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060131

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20060125

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090827

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090915

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121002

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121002

Year of fee payment: 3

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121002

Year of fee payment: 3

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131002

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees